{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:25:19Z","timestamp":1767165919803,"version":"build-2238731810"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Healthcare Engineering"],"published-print":{"date-parts":[[2022,3,29]]},"abstract":"<jats:p>\n                    Background. Multiple myeloma (MM) is one of the hitherto incurable malignant blood tumors. Bortezomib plays an important role in the treatment of MM. Objective. We aimed to compare effectiveness, safety, and pharmacoeconomic evaluations of the original research drug and the generic drug Bortezomib in the treatment of MM, so as to provide a reasonable basis for the selection of drugs in clinical diagnosis and treatment. Methods. A collection of 374 patients with MM were diagnosed and treated with combined Bortezomib in our hospital from July 2019 to January 2020.Two hundred and sixty nine cases met the criteria for inclusion and discharge. According to the different drug manufacturers, divided into the original research drug group (n\u2009=\u2009149) and the generic drug group (n\u2009=\u2009120). The effectiveness and safety were separately counted, and use the cost-minimization analysis to make the pharmacoeconomic evaluations. Results. Compared with the results of the two groups, there was no statistical difference between the two groups of treatment efficacy or adverse reaction rates (\n                    <jats:inline-formula>\n                      <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                      <\/a:math>\n                    <\/jats:inline-formula>\n                    \u2009&gt;\u20090.05). The average daily cost of the original research drug group was 2954.38 Chinese yuan (CNY), the average treatment cost per cycle was 32967.69 CNY, the average daily cost of the generic drug group was 2697.29 CNY, and the average treatment cost per cycle was 29129.57 CNY. The price of the generic drug group is lower than the original drug group, and there was a statistical difference between the two groups (\n                    <jats:inline-formula>\n                      <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                      <\/c:math>\n                    <\/jats:inline-formula>\n                    \u2009&lt;\u20090.05). Conclusion. There was no difference between the two groups of effectiveness or safety, and the generic drug is more economical in the treatment.\n                  <\/jats:p>","DOI":"10.1155\/2022\/5201354","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T19:05:16Z","timestamp":1648580716000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-1842","authenticated-orcid":true,"given":"Yongchao","family":"Liang","sequence":"first","affiliation":[{"name":"Capital Medical University, Beijing 100069, China"},{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"},{"name":"Jianguomen Community Health Service Center, Dongcheng District, Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"},{"name":"Xiaotangshan Hospital, Beijing 102211, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-7458","authenticated-orcid":true,"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-3173","authenticated-orcid":true,"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01513"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0706-9"},{"issue":"2","key":"3","first-page":"6","article-title":"The concept, progress and practice path of value-based healthcare","volume":"36","author":"C. L. Jin","year":"2019","journal-title":"Health Economics Research"},{"issue":"3","key":"4","first-page":"9+11","article-title":"China guidelines for pharmacoeconomic evaluations, China","volume":"6","author":"G. Liu","year":"2011","journal-title":"China Journal of Pharmaceutical Economic"},{"issue":"7","key":"5","first-page":"764","article-title":"Analysis of curative effect, hospitalization cost and cost-effect of different treatments for patients with multiple myeloma","volume":"20","author":"S. F. Wang","year":"2020","journal-title":"Chinese Journal of Evidence-Based Medicine"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70442-5"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.2267"},{"issue":"1","key":"9","first-page":"137","article-title":"Short-term efficacy and safety profile of generic bortezomib in the treatment of multiple myeloma","volume":"29","author":"R. Q. Liao","year":"2021","journal-title":"Journal of Experimental Hematology"},{"issue":"5","key":"10","first-page":"341","article-title":"The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)","volume":"59","author":"N. K. Z. Z. Zhonghua","year":"2020","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"15","key":"11","first-page":"2096","article-title":"Research status of bortezomib in the treatment of multiple myeloma","volume":"37","author":"Y. C. Liang","year":"2021","journal-title":"The Chinese Journal of Clinical Pharmacology"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v128.22.3558.3558"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20170304"},{"issue":"08","key":"14","first-page":"1275","article-title":"Clinical efficacy of domestic Bortezomib in the treatment of multiple myeloma and its safety","volume":"22","author":"Q. Wang","year":"2020","journal-title":"Journal of Chinese Physician"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30525-8"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1513487"},{"issue":"13","key":"17","first-page":"1164","article-title":"Analysis and discussion of generic drug consistency evaluation in NMPA and relevant drug policies in FDA and PMDA","volume":"30","author":"D. Li","year":"2021","journal-title":"Chinese Journal of New Drugs"}],"updated-by":[{"DOI":"10.1155\/2023\/9806864","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"record-id":"55518"},{"DOI":"10.1155\/2023\/9806864","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000}}],"container-title":["Journal of Healthcare Engineering"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/jhe\/2022\/5201354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jhe\/2022\/5201354.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/jhe\/2022\/5201354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T19:05:25Z","timestamp":1648580725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/jhe\/2022\/5201354\/"}},"subtitle":[],"editor":[{"given":"Liaqat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":17,"alternative-id":["5201354","5201354"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5201354","relation":{},"ISSN":["2040-2309","2040-2295"],"issn-type":[{"value":"2040-2309","type":"electronic"},{"value":"2040-2295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,29]]}}}